The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA considers adding a dozen peptides to its bulk drug compounding list RAPS BPC 157 Banned: Key Facts on the Latest FDA Decision FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea FDA to Convene Pharmacy Compounding Advisory Committee in July FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures kvue.com